Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Experimental Product Clear all
Recruiting Phase 1 Interventional

TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia

NCT06088888
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
TGRX-678
Drug
Lead sponsor
Shenzhen TargetRx Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 20, 2025 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Nicotinic Receptors and Schizophrenia

NCT01400477
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DMXB-A-SR, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 23, 2026, 10:09 PM EDT
Recruiting Phase 1 Interventional

ORB-021 In Patients With Advanced Solid Tumors

NCT06607939
View directory record Official record
Conditions
Advanced Solid Tumors Cancer
Interventions
ORB-021
Drug
Lead sponsor
Orionis Biosciences Inc
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Scottsdale, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Intranasal Heparin Tolerability Study

NCT04490239
View directory record Official record
Conditions
Covid19
Interventions
Intranasal heparin sodium (porcine)
Drug
Lead sponsor
Joshua Sharp
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
University, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose and Multiple Dose Trial to Assess Pharmacokinetics of Obeticholic Acid (OCA)

NCT01933503
View directory record Official record
Conditions
Healthy
Interventions
OCA 5 mg, OCA 10 mg, OCA 25 mg
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2013 · Synced Sep 23, 2026, 10:09 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Clinical Performance of the Investigational GEM Hemochron® 100 in Populations Ages 18 Years and Older

NCT03074266
View directory record Official record
Conditions
Blood Coagulation Test
Interventions
GEM Hemochron 100 ACT
Diagnostic Test
Lead sponsor
Accriva Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
9
States / cities
Los Angeles, California • Sacramento, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2018 · Synced Sep 23, 2026, 10:09 PM EDT
Recruiting Phase 2 Interventional

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
NNC0662-0419, Semaglutide, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Lancaster, California • Lomita, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 10:09 PM EDT
Terminated Phase 2 Interventional

Effect of Over-the-counter Toothpastes on Chemotherapy-induced Oral Mucositis

NCT02606994
View directory record Official record
Conditions
Mucositis, Neoplasms
Interventions
Oral Defense Toothpaste, Crest Toothpaste, Magic Mouth Rinse
Drug
Lead sponsor
Oral Defense, LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 23, 2026, 10:09 PM EDT
Terminated Phase 1 Interventional

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

NCT01130688
View directory record Official record
Conditions
Chronic Myelogenous Leukemia
Interventions
Zileuton
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

NCT03889886
View directory record Official record
Conditions
Dry Eye
Interventions
SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
26
States / cities
Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Sep 23, 2026, 10:09 PM EDT
Withdrawn Phase 2 Interventional

Targeted Vitamin D Treatment of Schizophrenia-Associated Hyperprolinemia

NCT02197286
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Cholecalciferol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 11, 2015 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of an Oral Plasmodium Falciparum Plasma Membrane Protein Inhibitor

NCT02661373
View directory record Official record
Conditions
Malaria
Interventions
SJ733, Cobicistat
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 1, 2019 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Not applicable Interventional

Evaluation of an Ayurvedic Herbal Compound Compared to Vitamins C+E and Placebo on Vascular Function in High-Risk Subjects

NCT07206901
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Maharishi Amrit Kalash, vitamin C + E, Inert Placebo Capsule
Dietary Supplement · Other
Lead sponsor
Maharishi International University
Other
Eligibility
55 Years to 90 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
1
States / cities
Fairfield, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 2 Interventional

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

NCT00034957
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
Interventions
Investigational drug
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2002
U.S. locations
12
States / cities
Berkeley, California • Greenbrae, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2012 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Trial To Evaluate ANT-1207 In Subjects With Crow's Feet

NCT01358695
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet
Interventions
ANT-1207, Botulinum Toxin Type A
Biological
Lead sponsor
Anterios Inc.
Industry
Eligibility
30 Years to 70 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Birmingham, Alabama • Miami Beach, Florida • West Palm Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2013 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Not applicable Interventional

A Pilot Pharmacokinetic Phase I Evaluation of BI-RG-587 in HIV-Infected Children

NCT00000634
View directory record Official record
Conditions
HIV Infections
Interventions
Nevirapine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 13 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 28, 2011 · Synced Sep 23, 2026, 10:09 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Capecitabine, Gemcitabine, Eribulin, Vinorelbine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
14
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 3 Interventional

PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial

NCT05511922
View directory record Official record
Conditions
Hereditary Angioedema
Interventions
KVD900 600 mg, Drug: KVD900 300 mg
Drug
Lead sponsor
KalVista Pharmaceuticals, Ltd.
Industry
Eligibility
12 Years to 17 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 23, 2026, 10:09 PM EDT
Recruiting Phase 4 Interventional

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

NCT06953271
View directory record Official record
Conditions
Overactive Bladder (OAB), Urinary Tract Infection (Diagnosis)
Interventions
Methenamine Hippurate, Typically prescribed oral antibiotic prophylaxis
Drug
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 1 Interventional

DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis

NCT03305471
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
DS-2330b PIB, Placebo, Sevelamer, DS-2330b Tablet
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Lakewood, Colorado • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Sep 23, 2026, 10:09 PM EDT
Recruiting Phase 2 Interventional

Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

NCT05604131
View directory record Official record
Conditions
Acute Myocardial Infarction Type 1
Interventions
Deferiprone Tablets, Placebo
Drug
Lead sponsor
Rohan Dharmakumar
Other
Eligibility
18 Years to 79 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers

NCT04092712
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[14C]-CTP-543
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Sep 23, 2026, 10:09 PM EDT
Terminated Phase 1 Interventional

Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease

NCT04070781
View directory record Official record
Conditions
Steroid Refractory GVHD, Graft Vs Host Disease
Interventions
Itacitinib, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2024 · Synced Sep 23, 2026, 10:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban

NCT01826266
View directory record Official record
Conditions
Anticoagulant Reversal, Reversal of Edoxaban Induced Anticoagulation
Interventions
PER977, Placebo
Drug
Lead sponsor
Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Sep 23, 2026, 10:09 PM EDT